Objective
- Continue a prospective collection of clinical, laboratory and therapeutic data on a large cohort of unselected HIV infected patients from all parts of Europe. This to monitor the pattern of HIV-associated illnesses and prognosis among these patients on an European level.
-Introduce determinations of the HIV viral load in serum as a prognostic marker in this cohort and assess its use in patient monitoring (compared with clinical presentation and CD4 count).
- Collect plasma for subsequent analyses of other soluble markers which may serve as prognostic markers of specific markers of certain types of HIV-associated diseases.
The EuroSIDA study will be able to give an up-to-date assessment of the overall impact of the interventions that patients infected with HIV are offered on a European level. A total of more than 7500 unselected patients from 48 clinical centres in 18 European countries will be subjected to long-term follow-up, of whom 4500 are currently followed as of January 1997 as part of the EuroSIDA 1994-1997 study. New patients will be recruited periodically, to ensure that the study will give-up-to-date information on the clinical presentation and outcome of European patients infected with HIV. The EuroSIDA 1997-2000 study will initiate the determination of HIV RNA load in plasma. This will serve as a valuable additional prognostic marker, based on results now emerging from small patient-sample studies. Furthermore, we will be able to assess to what extend the HIV load can be used in patient monitoring. Results of HIV RNA load determinations and several thousand plasma samples will be collected. The plasma will also be used to assess other prognostic markers which may become available, in addition to study the epidemiology of HIV subtypes and of the development of genotypic antiretroviral resistance patterns. The organisation of the data collection and the collaboration between the centres involved in the EuroSIDA 1994-1997 study have been successful, with the collection of high quality data and a low loss-to-follow-up rate.
Europe is the ideal place to perform long-term cohort studies because of a well organised infrastructure and good follow-up of the patients. Thus, the EuroSIDA study will most likely be the largest global cohort study of unselected patients with the collection of detailed data related to the HIV infection and long-term follow-up .
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences public health epidemiology
- medical and health sciences health sciences infectious diseases RNA viruses HIV
- natural sciences biological sciences genetics RNA
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
2650 HVIDOVRE
Denmark
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.